Joseph Michael Young, Ph.D. 1 Hampshire Road Madison, CT 06443

Phone: (617)460-3008 (cell) Email: joseph.michael.young@gmail.com

Medicinal Chemist 7 years of pharmaceutical industry drug discovery experience and 15+ years of experience in

organic chemistry. Broad knowledge of medicinal chemistry and its application to small-molecule drug discovery. Extensive experience with all aspects of synthetic chemistry, including recent advances in the

chemistry literature, reaction mechanism and small-to-large scale multi-step synthesis; capable of designing and enabling new reactions and routes based on this understanding.

Proven project leader capable of delivering drug candidates while working across business lines and with external partners.

Experience in leading chemistry teams to achieve project goals with complex chemistry targets. Significant experience with parallel medicinal chemistry, from library design to enablement to

execution. Established ability to work with Contract Research Organizations (CRO) to seamlessly interface

with internal chemistry team for effective project advancement.

Pharmaceutical Industry Experience: Neuroscience Chemistry, Pfizer Worldwide R&D, Groton, CT Principal Scientist (June 2011-present)

As a lab head in Neuroscience Medicinal Chemistry, managed teams of 2-5 internal chemists and up to 7 external chemists across four programs from hit-to-lead through candidate selection, across several indications and target classes.

As synthesis lead, delivered projects in conjunction with design lead. o Performed target route design and selection based on understanding of SAR and desired

compound profile. Balanced internal enablement of key disconnections and novel targets with external or library execution of most analogs. Teams synthesized a wide variety of novel (multi-cyclic) heterocycles with varying degrees of unsaturation and multiple stereogenic centers.

o Conceived new reactions and routes, and provided solutions to problematic chemistry as scientific lead.

o As personnel manager, insured that the skills of the chemists were aligned with the targets they were responsible for.

o Regularly brought forward ideas to access areas of improved physicochemical property space through enablement of new vectors or modifying approaches to known vectors.

o Combined in-depth knowledge of binding sites with excellent grasp of molecular conformation and electronics to design novel compounds with improved potency or selectivity.

o Responsible for meeting material needs for compound profiling from beginning in vitro assays through non-regulatory toxicology studies (5 mg to 75 grams).

o Ensured facile technology transfer to the process group, including improving scalability of chemistry through route and reaction optimization, sourcing raw materials, and communicating with my counterparts in development.

o Sourced key intermediates to drive uninterrupted project progression based on my understanding of timelines and key studies.

o Worked with counterparts in Formulations to anticipate and solve solid form and dosing issues.

Lead the Neuroscience parallel synthesis team, a combination of internal and external resources utilized by all programs. o Worked closely with project teams at all stages to successfully transform single-analog

routes into library-enabled protocols. o Supported early stage programs by helping select library-enabled routes that provided

access to the largest possible chemical space. o Set guidelines for library submission quality and site of prosecution (internal vs external) in

addition to providing budget guidance. Neuroscience Contract Research Organization (CRO) Leadership

o Crafted guidelines for NS department CRO interactions (communication, request writing, the types of chemistry we should send, how much enablement needed to be done prior to external work) that helped improve compound flow (time in queue) and rate (number of compounds/month) metrics.

o Outsourcing point-of-contact (POC) for my programs for two years Oversaw daily interactions with the CRO team, target and route selection, problem

solving. My CRO team contributed significantly to the success of the projects and met or

exceeded desired compound flow and rate metrics Senior Scientist (September 2008-June 2011)

Contributor to beta-secretase inhibition program. Key contributions to lead spiropiperidine series include: o Optimized Goldberg amide arylation conditions to improve yields, and provide access to

important 5- and 6-membered heterocycles; used during the pre-regulatory synthesis of clinical candidate PF-5297909 (50-100g).

o Designed and executed a range of ring size variants to the lead lactam series to probe effect on clearance and permeability.

o With other team members, designed and executed an Overman-rearrangement sequence to improve the diastereoselectivity, and thus the overall yield, of the lead compounds’s synthesis, and provide access to key 3-subsituted lactams

o Designed and executed a series of cyclic sulfonamides with dramatically improved potency that combined key features of several lead series. Conceived a novel sulfonylation/Dieckman sequence to access these.

o Ran the CRO team supporting the program. Improved overall productivity by shifting team away from lengthy high-synthetic risk targets to more high-value, less lengthy targets, and by actively helping our external team solve chemistry issues.

Education: Ph.D, Chemistry, Harvard University (September 2002-July 2008) Prof. David A. Evans, Department of Chemistry and Chemical Biology Studies Toward the Synthesis of Aflastatin A B.S. with High Distinction, Chemistry, University of Minnesota, Twin Cities (September 1999-May 2002) Undergraduate Research with Prof. Thomas R. Hoye Studies Toward the Synthesis of Spiruchostatin A Awards and Fellowships: 2007-2008 Eli Lilly Graduate Research Fellowship 2002-2005 NSF Graduate Research Fellowship Publications and Presentation:

1. Young, Joseph M.; Chandrasekaran, Ramalakshmi; Lee, Aisha; Tucker, Joseph W., “Sulfonamides without oxidation: The Burgess reagent as high valent sulfur source”, manuscript in preparation

2. Butler, Christopher; Brodney, Michael; Beck, Elizabeth; Barreiro, Gabriela; Nolan, Charles; Pan, Feng; Vajdos, Felix; Parris, Kevin; Varghese, Alison; Helal, Christopher; Lira, Ricardo; Doran, Shawn; Riddell, David; Buzon, Leanne; Dutra, Jason; Martinez-Alsina, Luis; Ogilvie, Kevin; Murray, John; Young, Joseph; Atchison, Kevin; Robshaw, Ashley; Gonzales, Cathleen; Wang, Jinlong; Zhang, Yong; O'Neill, Brian “Discovery of a Series of Efficient, Centrally Efficacious BACE1 Inhibitors through Structure-Based Drug Design”, J. Med. Chem, ASAP (DOI: 10.1021/jm501833t).

3. Young, Joseph M.; Chandrasekaran, Ramalakshmi; Lee, Aisha; Tucker, Joseph W., “Sulfonamides without oxidation: The Burgess reagent as high valent sulfur source”, 248th ACS National Meeting & Exposition, San Francisco, CA, United States, August 10-14, 2014 (Presentation).

4. Lee, Che-Wah; Lira, Ricardo; Dutra, Jason; Ogilvie, Kevin; O'Neill, Brian T.; Brodney, Michael; Helal, Christopher; Young, Joseph; Lachapelle, Erik; Sakya, Subas; Murray, John C. “Stereoselective Synthesis of Spiropiperidines as BACE-1 Aspartyl Protease Inhibitors via Late Stage N-Arylation of a 1,8-Diazaspiro[4.5]dec-3-en-2-one Pharmacophore”, J. Org. Chem. 2013, 78, 2661-2669.

5. Li, Bryan; Widlicka, Daniel; Boucher, Steven; Hayward, Cheryl; Lucas, John; Murray, John C.; O'Neil, Brian T.; Pfisterer, David; Samp, Lacey; VanAlsten, John; Xiang, Yanqiao; Young, Joseph “Telescoped Flow Process for the Syntheses of N-Aryl Pyrazoles”, Org. Process Res. Dev., 2012, 16, 2031-2035.

Patents: 1. PC72145 2. PC72146